0715 ET - Hims & Hers has backtracked on plans to release a compounded semaglutide pill following threats from the FDA and DOJ, raising questions about why it tried to push forward in the first place, say Morgan Stanley analysts. "Even before FDA and DOJ involvement, feedback was nearly unanimous that this move was aggressive and would not likely stand up," the analysts say. There could now be increased scrutiny on compounded GLP-1 injectables. "While compounding is permitted under limited circumstances, regulators have cautioned that marketing compounded products in a manner that implies comparable effects to FDA-approved drugs may be misleading," the analysts say. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

February 09, 2026 07:15 ET (12:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.